Clinical & Experimental Metastasis

, Volume 22, Issue 7, pp 565–573

MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer

  • Paul J. Cozzi
  • Jian Wang
  • Warick Delprado
  • Alan C. Perkins
  • Barry J. Allen
  • Pamela J. Russell
  • Yong Li
Article

DOI: 10.1007/s10585-005-5376-z

Cite this article as:
Cozzi, P.J., Wang, J., Delprado, W. et al. Clin Exp Metastasis (2005) 22: 565. doi:10.1007/s10585-005-5376-z

Abstract

Molecular changes are vital for the development of prognostic markers and therapeutic modalities of prostate cancer (CaP). There is growing interest in mucins as treatment targets in human malignancies, including CaP. The role of their expression in the progression of CaP is however unclear. We examined the expressions MUC1, MUC2, MUC4, MUC5AC and MUC6 in CaP tissues using tissue microarrays (TMAs) to look for tumor-associated antigens (TAAs) for targeted therapy. In this study, 120 paraffin-embedded specimens were selected from patients who underwent radical retro-pubic prostatectomy (RRP) or trans-urethral-resection of the prostate (TURP) for primary, untreated CaP and 10 matched lymph node metastases. A series of MUC monoclonal antibodies (mAbs) was used on TMAs by standard immunohistochemistry. Our results indicate that the over-expression of MUC1 was detected in 58% of primary CaP tissues and 90% of lymph node metastases but not in normal prostate or benign tissues, while the expression of MUC2, MUC4, MUC5AC and MUC6 was found to be negative in both normal and cancer tissues. Of the MUC1 positive tumors 86% were Gleason grade 7 or higher. Over-expression of MUC1 was found in late stage CaP while MUC2, 4, 5AC and 6 were negative in CaP. MUC1 is a TAA that is highly related to tumor progression in CaP patients. This antigen is ideal for targeted therapy to control micrometastases and hormone refractory disease but additional studies are necessary to assess its usefulness in patient biopsies and CaP bone metastases before clinical trial.

Keywords

human prostate cancermonoclonal antibodiesmucinstissue microarraytumor-associated antigen

Abbreviations

CaP

prostate cancer

mAbs

monoclonal antibodies

MRD

minimal residual disease

PIN

prostatic intra-epithelial neoplasia

PSA

prostate-specific antigen

RRP

radical retro-pubic prostatectomy

SIGLECS

sialic-acid-binding immunoglobulin superfamily lectins

SMC

sialomucin complex

TBS

tris buffered saline

TAA

tumor-associated antigens

TMA

tissue microarrays

TURP

trans-urethral-resection of the prostate

Copyright information

© Springer 2006

Authors and Affiliations

  • Paul J. Cozzi
    • 1
    • 2
  • Jian Wang
    • 2
    • 3
  • Warick Delprado
    • 4
  • Alan C. Perkins
    • 5
  • Barry J. Allen
    • 2
    • 3
  • Pamela J. Russell
    • 2
    • 6
  • Yong Li
    • 2
    • 3
  1. 1.Department of SurgerySt George HospitalKogarahAustralia
  2. 2.Department of MedicineUniversity of New South WalesKensingtonAustralia
  3. 3.Center for Experimental Radiation Oncology, Cancer Care CenterSt George HospitalKogarahAustralia
  4. 4.Douglass Hanly Moir PathologyNorth RydeAustralia
  5. 5.Department of Medical Physics, Medical SchoolQueen’s Medical CentreNottinghamUnited Kingdom
  6. 6.Oncology Research CenterPrince of Wales HospitalRandwickAustralia